ASCEND BY NTHRYS
Research Abroad Products

Molecular Biomarkers Project Topics

Browse all focused areas across all project categories under this field.

Showing 25–36 of 200 project topics
MicroRNA Expression Signature SaaS for Cancer Prognosis Prediction
A subscription-based software platform that quantifies circulating miRNA signatures from liquid biopsy samples and predicts patient outcomes, treatment response, and survival probability using proprietary machine learning models. Oncology centers pay per-patient analysis fees, generating predictable recurring revenue while enabling clinicians to make personalized treatment decisions and improve patient stratification in clinical trials.
Cancer Liquid Biopsy Biomarker Development Click to view more details →
Fragmentation Pattern Analysis Engine for Tumor DNA Profiling
A specialized software tool that analyzes cell-free DNA fragment length and end-motif patterns as non-invasive markers of tumor biology, clonal evolution, and treatment response without requiring mutation detection. Diagnostic companies integrate this technology into their liquid biopsy workflows to provide differentiated insights, enabling premium pricing strategies and enhanced clinical utility that justifies higher reimbursement rates.
Cancer Liquid Biopsy Biomarker Development Click to view more details →
Protein-based Cancer Biomarker Multiplex Detection System
An immunoassay-based diagnostic instrument and cartridge system that simultaneously measures 20+ cancer-associated proteins from a single blood sample with point-of-care or laboratory deployment options. The company generates revenue through instrument sales, monthly service contracts, and high-margin cartridge consumables, while enabling rapid triage and monitoring across hospital networks and outpatient oncology practices.
Cancer Liquid Biopsy Biomarker Development Click to view more details →
Genomic Instability Index Platform for Treatment Selection
A data analytics platform that calculates tumor burden-normalized genomic instability metrics from ctDNA sequencing data to predict immunotherapy and targeted therapy responsiveness. Clinical laboratories and pharma companies license this tool on a per-test or subscription basis, enabling precision treatment selection that improves clinical outcomes and justifies premium diagnostic pricing in high-value oncology markets.
Cancer Liquid Biopsy Biomarker Development Click to view more details →
Liquid Biopsy Data Integration and Clinical Reporting Dashboard
A cloud-based electronic health record integration platform that consolidates multi-analyte liquid biopsy results (ctDNA, CTCs, exosomes, proteins) with clinical data for unified patient monitoring dashboards. Hospitals and oncology networks subscribe to this platform to streamline clinical workflows, reduce reporting turnaround time by 50%, and enable longitudinal biomarker tracking that drives improved patient outcomes and competitive market positioning.
Cancer Liquid Biopsy Biomarker Development Click to view more details →
Tumor Heterogeneity Profiling Service via Multi-omics Liquid Biopsy
A comprehensive laboratory service that performs simultaneous genomic, transcriptomic, and proteomic analysis on circulating tumor material to map tumor clonal diversity and spatial heterogeneity. Academic medical centers and pharma companies pay premium fees for this service to support precision oncology research and adaptive clinical trial designs, generating high-value service revenue while establishing technology leadership in tumor biology understanding.
Cancer Liquid Biopsy Biomarker Development Click to view more details →
Real-time Biomarker Data Integration and Analytics Platform
A cloud-based SaaS platform that aggregates multi-omics biomarker data from clinical laboratories and medical devices in real-time. Enables healthcare providers and pharmaceutical companies to reduce time-to-insight by 60% and accelerate drug development decision-making through unified data visualization and predictive modeling.
Predictive Biomarker Clinical Validation Platforms Click to view more details →
AI-Powered Predictive Biomarker Stratification Engine
An intelligent machine learning platform that automatically identifies and validates patient subpopulations based on molecular biomarker profiles for precision medicine applications. Generates recurring licensing revenue while reducing clinical trial costs by enabling more targeted patient enrollment and improving success rates.
Predictive Biomarker Clinical Validation Platforms Click to view more details →
Clinical Laboratory Information System with Biomarker Management
A comprehensive LIMS solution specifically designed to validate, track, and report predictive biomarker results with full regulatory compliance and audit trails. Delivers enterprise SaaS revenue through laboratory licensing fees while reducing operational costs and improving report turnaround time by 40%.
Predictive Biomarker Clinical Validation Platforms Click to view more details →
Biomarker Companion Diagnostic Development and Validation Toolkit
A modular software suite that streamlines the entire CDx development workflow from biomarker discovery through clinical validation and regulatory submission. Monetizes through tiered licensing and professional services while reducing time-to-market for companion diagnostics by 18-24 months.
Predictive Biomarker Clinical Validation Platforms Click to view more details →
Multi-Platform Biomarker Assay Performance Benchmarking Service
A commercial testing and analytics service that compares and validates predictive biomarker assay performance across different platforms and laboratories. Generates revenue through per-assay testing fees while providing critical data for clinical laboratories and diagnostics manufacturers to establish market credibility.
Predictive Biomarker Clinical Validation Platforms Click to view more details →
Integrated Biomarker-Phenotype Clinical Data Exchange Network
A secure, interoperable cloud platform that enables seamless sharing of validated biomarker data and patient phenotypes between healthcare systems, research institutions, and pharmaceutical sponsors. Creates sustainable revenue through data access licensing and enables partners to unlock previously siloed patient cohorts worth millions in research value.
Predictive Biomarker Clinical Validation Platforms Click to view more details →